PUBLICATION
SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition
- Authors
- Chen, X., Fu, Y., Xu, H., Teng, P., Xie, Q., Zhang, Y., Yan, C., Xu, Y., Li, C., Zhou, J., Ni, Y., Li, W.
- ID
- ZDB-PUB-180316-4
- Date
- 2017
- Source
- Oncotarget 9: 10891-10904 (Journal)
- Registered Authors
- Keywords
- EMT, SOX5, lung adenocarcinoma, prognosis
- MeSH Terms
- none
- PubMed
- 29541384 Full text @ Oncotarget
Citation
Chen, X., Fu, Y., Xu, H., Teng, P., Xie, Q., Zhang, Y., Yan, C., Xu, Y., Li, C., Zhou, J., Ni, Y., Li, W. (2017) SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition. Oncotarget. 9:10891-10904.
Abstract
Lung cancer is the leading cause of cancer-related death worldwide. Epithelial-mesenchymal transition (EMT) promotes lung cancer progression and metastasis, especially in lung adenocarcinoma. Sex determining region Y-box protein 5 (SOX5) is known to stimulate the progression of various cancers. Here, we used immunohistochemical analysis to reveal that SOX5 levels were increased in 90 lung adenocarcinoma patients. The high SOX5 expression in lung adenocarcinoma and non-tumor counterparts correlated with the patients' poor prognosis. Inhibiting SOX5 expression attenuated metastasis and progression in lung cancer cells, while over-expressing SOX5 accelerated lung adenocarcinoma progression and metastasis via EMT. An in vivo zebrafish xenograft cancer model also showed SOX5 knockdown was followed by reduced lung cancer cell proliferation and metastasis. Our results indicate SOX5 promotes lung adenocarcinoma tumorigenicity and can be a novel diagnosis and prognosis marker of the disease.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping